ProductDescription
NVP-BGT226isanovelorallybioavailabledualPI3K/mTORinhibitor.ItselectivelyinhibitsPI3KandbothmTORcomplexesmTORC1andmTORC2,resultinginnearlycompletephosphorylation-inhibitionofP70S6and4E-BP1.
BGT226demonstratedexcellentcellularactivitiesininhibitingproliferations(IC50:7-30nM)ofmanytestedcelllines.Notably,cellsthatexpressPIK3CAmutationH1047Rarestillsensitivetothegrowth-inhibitionofBGT226.FlowcytometricanalysisshowsaccumulationofcellsintheG0-G1phasewithconcomitantlossintheS-phase.BGT226inducesapoptosisorautophagyofsomecancercellsatIC50lessthan25nM.Inanimalmodels,BGT226significantlydelays/inhibitstumorgrowthinadose-dependentmanner.BGT-226representsapotentialcandidateforcancertherapy.IthasenteredphaseI/IIclinicaltrialsfortreatmentofadvancedsolidtumors(includingbreastcancer)[1-4].
Technicalinformation:
| ChemicalFormula: | C28H25F3N6O2.C4H4O4 | |
| CAS#: | 1245537-68-1 | |
| MolecularWeight: | 650.6 | |
| Purity: | >98% | |
| Appearance: | White | |
| ChemicalName: | 8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-oneMaleicacid | |
| Solubility: | Upto22mMinDMSO | |
| Synonyms: | NVP-BGT226,BGT226 |
ShippingCondition:Theproductisshippedinaglassvialatambienttemperature.
Storagecondition:Forlongershelflife,storesolidpowderat4oCdesiccated,orstoreDMSOsolutionat-20oC.
Reference:
| 1. | BaduraS,etal.PosterAbstracts.DifferentialSuppressiveEffectsofSelectivePI3KandmTORandDualPI3K/mTORC1/C2InhibitiononLong-TermCulturedPrimaryHumanAcuteLymphoblasticLeukemia(ALL)CellsImplicateaDistinctRoleofmTORC2https://ash.confex.com/ash/2010/webprogram/Paper33127.html |
| 2. | ChangKY,etal.Novelphosphoinositide3-kinase/mTORdualinhibitor,NVP-BGT226,displayspotentgrowth-inhibitoryactivityagainsthumanheadandneckcancercellsinvitroandinvivo.ClinCancerRes.2011.17(22):7116-26.PubmedID:21976531 |
| 3. | BaumannP,etal.SimultaneoustargetingofPI3KandmTORwithNVP-BGT226ishighlyeffectiveinmultiplemyeloma.AnticancerDrugs.2012.23(1):131-8.PubmedID:21959532 |
| 4. | http://clinicaltrials.gov/ct2/show/NCT00600275 |
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
、
Cell-Based ELISA
的优点:
Cell-Based ELISA
(基于细胞的
ELISA
)是一种全新的
ELISA
技术,有两个最突出的优点:
1.1
不需要抽提蛋白、包被微孔板:细胞直接在微孔板里培养,待检测的时候,将细胞固定在微孔板上并
进行通透处理即可。这样就避免了抽提蛋白时,由于客观和主观上引起样品的损失而导致实验结果在一定
程度上偏离了实际情况。
同时不用包被微孔板,
简化了实验流程,
有助于提高效率。
科研人员在一个
96
孔
酶联板上,便能检测目标细胞蛋白经刺激或抑制作用后的表现。由于省去抽提蛋白和裂解细胞的步骤,样
本的损失也能降到最低,比起其他普通的
ELISA
测定方法,这项全新的
ELISA
技术能更快速、更方便
地一次检测大量的细胞内蛋白。
1.2
可同时检测两种不同蛋白:
封闭后加入两种抗不同蛋白且来源于不同宿主的一抗,
然后再加入不同的
二抗,加入两种荧光底物,检测两个波长。同时检测两种蛋白的好处是显而易见的,可以减少工作量,此
外还可以满足一些特殊的实验需要,例如,需要测定某个蛋白的磷酸化比例,就需要测定磷酸化蛋白的数
量和总蛋白的数量,这两个测定在同一次实验进行,有助于消除实验误差,得到更为精确的实验结果。
2
、
Cell-Based ELISA
的两种技术:
某些公司发展了双通道
Cell-Based ELISA
技术;
双通道与单通道
Cell-based ELISA
比较:
双通道
cell-based ELISA
,顾名思义,即一次可以同时检测两种目的蛋白,
R&D Systems
提供的
Cell-based ELISA
就是双通道
cell-based ELISA
,原理略:(需要荧光检测方式和相应仪器);
单通道
cell-based ELISA
,即一次只能检测一种目的蛋白,他和普通
ELISA
的主要区别在于样品处理过
程
3
、
cell-based ELISA
的应用:
该产品,最多发展起来的是用于检测磷酸化和非磷酸化蛋白的相对含量;
4
、有
cell-based ELISA
产品的公司:目前,多家
elisa
产品提供
商均
提供
cell
based
elisa
试剂盒,
如
Rnd
systems
,
raybiotech
,
ebioscience
,
millipore
等公司;
5
、如何自己进行
cell based elisa
实验?
事实上,根据单通道的
cell based elisa
原理,可以自己建立
cell based elisa
实验系统;
细胞加入培养板中;
加入刺激物或者抑制剂进行培养;
对细胞进行固定或者封闭;
加入第一抗体;
加入
HRP
结合的二抗(二抗的选择,同
western blot
);
加入底物进行显色;
我做的是细胞因子的刺激和抑制某条通路后观察是否有影响,分组为空白组,空白+抑制剂,刺激组,刺激+抑制剂,最开始用的单因素方差分析,LSD-T和SNK-Q检验,但是同学说我这里面有两个处理因素,所以不能单因素方差分析,应该直接空白和空白+抑制,空白和刺激,刺激和刺激+抑制剂进行独立样本T检验,现在脑子是混乱的,拜托园子里的大神们帮我看看,感激不尽!!
支原体培养则是取样后在培养基上培养,看有多少支原体菌落会长出,是比较直观和可信的结果。
总体来讲,这两种检查手段可信度都较高,结合一起,不仅可以可靠的知道有无解脲支原体感染,还能知道感染是否严重。
认领翻译的战友请跟帖注明“认领本文翻译,48小时内未完成,请其他站友认领”
MaggotsFasterThanScalpelinWoundDebridement
December19,2011—Maggotdebridementtherapy(MDT)appearstobemoreeffectiveforwounddebridementcomparedwithconventionaltherapy,butonlyat1week;afterthattime,anothertypeofdressingshouldbeused,newresearchsuggests.
KristinaOpletalovà,MD,fromtheDepartmentofDermatology,UniversityofCaen,France,andcolleaguespublishedonlineDecember19intheArchivesofDermatology.
MedicalmaggotswereapprovedbytheUSFoodandDrugAdmiNISTrationasamedicaldeviceforwounddebridementin2004.Accordingtotheresearchers,useofmaggotsintreatingwoundsisassociatedwitheffectivewounddebridement,antibacterialeffects,andstimulationofwoundhealing.
However,theypointout,"[r]elativelyfewclinicalstudieshavebeenconductedandtheresultsarenotclear,partlyowingtomethodologicassessmentproblems."
InthecurrentProspective,randomizedcontrolled,phase3clinicaltrial,theresearcherssoughttodeterminetheefficacyofbaggedlarvaeonwounddebridementincomparisonwithconventionaltreatment.
TheprimaryobjectivewastocomparethemeanpercentageofsloughinwoundstreatedwithMDTwiththatofconventionaltreatmentatday15.Thestudyincluded119patientswithanonhealing,sloughywoundthatwas40cm2orsmallerandlessthan2cmdeep.Patientsalsohadananklebrachialindexof0.8orhigher.
Treatmentwasadministeredduringa2-weekhospitalstay.Conventionaltreatmentconsistedofsurgicaldebridement3timesaweekwithascalpel,withuseoftopicalanesthesia.TheMDTwasadministeredusinganencloseddressing(Vitapad,BioMondeLaboratories)containing80sterilemaggots.Atdischarge,aconventionaldressingwasapplied,andpatientswerefollowed-upatday30.
DebridementbyMDTwassignificantlyfasterthansurgicaldebridementduringthefirstweekoftreatment,reachingthesamelevelthecontrolgroupreachedatday15.NobenefitforMDTcomparedwithconventionaltreatmentinhealingrateswasobserved.Atday8,54.5%intheMDTgroupvs66.5%inthecontrolgroup(P=.04)hadevidenceofsloughandwoundhealing.However,byday15,themeanpercentageofsloughwas55.4%intheMDTgroupand53.8%inthecontrolgroup(P=.78).
"AthoughMDTshowsnosignificantbenefitatday15comparedwithconventionaltreatment,debridementbyMDTissignificantlyfasterandoccursduringthefirstweekoftreatment,"theresearchersconclude."Becausethereisnobenefitincontinuingthetreatmentafter1week,anothertypeofdressingshouldbeusedafter2or3applicationsofMDT."
Painscoresweresimilarandmildinbothgroups,althoughincontrasttoconventionaltreatment,MDTwasperformedwithouttopicalanesthesia.
Accordingtotheresearchers,noneofthepatientswerereticentaboutundergoingMDT."[A]crawlingsensationonthewoundwasrarelyandalmostequallynotedinbothgroups,revealingthatthesensationwassubjective,"Dr.Opletalovàandcolleaguespointout.
TwoquestionsregardingMDTremainunanswered,theauthorsnote."Candebridementbeimprovedusingmoremaggotsperdressing?Ifso,wouldthesedressingsbemorepainful?Furtherstudiesareneededtoanswerthesequestions."
ThestudywassupportedbygrantsfromtheClinicalResearchHospitalProgramandfromtheFrenchSocietyofDermatology.Theauthorshavedisclosednorelevantfinancialrelationships.

